리서치사:Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
발행일:2025년 10월
페이지 정보:영문 194 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 올리고뉴클레오티드 합성 시장은 2030년까지 199억 달러에 이를 전망
2024년에 83억 달러로 추정되는 올리고뉴클레오티드 합성 세계 시장은 2024-2030년 분석 기간 중에 15.6%의 연평균 복합 성장률(CAGR)로 성장하여 2030년에는 199억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 올리고뉴클레오티드 기반 의약품은 CAGR 17.3%를 나타내고, 분석 기간 종료까지 86억 달러에 이를 것으로 예측됩니다. 합성 올리고뉴클레오티드 부문의 성장률은 분석 기간중 CAGR 15.0%로 추정됩니다.
미국 시장은 22억 달러로 추정, 중국은 CAGR21.2%를 보일 것으로 예측
미국의 올리고뉴클레오티드 합성 시장은 2024년에는 22억 달러에 이를 것으로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 49억 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 21.2%로 추정됩니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 11.1%와 13.1%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 약 12.2%를 보일 것으로 예측됩니다.
세계 올리고뉴클레오타이드 합성 시장 - 주요 동향 및 촉진요인 정리
올리고뉴클레오타이드 합성이란 무엇이며, 왜 세계에서 주목받는가?
올리고뉴클레오티드 합성이란 DNA와 RNA의 구성요소인 뉴클레오티드의 짧은 염기서열을 만드는 화학적 과정을 말합니다. 이러한 합성 올리고뉴클레오티드는 진단 및 치료에서 유전자 연구 및 생명공학에 이르기까지 다양한 응용 분야에 필수적입니다. 합성 과정을 통해 DNA와 RNA 사슬을 맞춤 제작할 수 있는 능력은 분자생물학에 혁명을 가져왔고, 연구자들은 표적 유전자 개입, 유전자 편집, 의약품 개발을 위한 특정 서열을 설계할 수 있게 되었습니다. 올리고뉴클레오티드는 PCR(중합효소연쇄반응), DNA 염기서열 분석, 유전자 합성, 항센스 치료제 등의 응용을 지원하며 현대 생명공학에서 중요한 역할을 하고 있습니다. 중요한 실현 기술인 올리고뉴클레오티드 합성은 유전체학, 맞춤의료, 신약개발의 획기적인 발전을 뒷받침하고 있으며, 생명과학과 헬스케어에 필수적인 요소로 자리 잡고 있습니다.
기술은 어떻게 올리고뉴클레오타이드 합성을 발전시키고 있는가?
기술의 발전은 올리고뉴클레오타이드 합성의 진화에 있어 매우 중요하며, 더 높은 정확도, 확장성, 생산 공정의 효율화를 촉진하고 있습니다. 자동 합성기 및 개선된 고체상 합성법과 같은 기술 혁신으로 인해 올리고뉴클레오타이드의 생산 속도가 크게 빨라져 제약 및 생명공학 산업 증가하는 수요를 쉽게 충족시킬 수 있게 되었습니다. 또한, 최근 하이스루풋 합성 기술의 발전으로 대규모 올리고뉴클레오타이드 라이브러리의 병렬 생산이 가능해져 유전자 편집 및 CRISPR 기술과 같은 분야에서 신속한 연구가 가능해졌습니다. 차세대 시퀀싱(NGS) 기술의 등장으로 고품질 올리고뉴클레오티드에 대한 수요가 더욱 증가하고 있습니다. NGS 워크플로우에서는 정확한 맞춤형 시퀀싱이 필수적이기 때문입니다. 각 업체들은 합성 올리고뉴클레오타이드의 순도, 길이, 염기서열의 충실도를 높이기 위해 많은 투자를 하고 있으며, 유전자 연구와 분자진단에서 달성할 수 있는 한계에 도전하고 있습니다.
올리고뉴클레오타이드가 치료와 진단에 필수적인 이유는 무엇인가?
올리고뉴클레오타이드의 치료 및 진단용에 대한 관심이 높아지면서 시장의 중요한 촉진제가 되고 있습니다. 치료제에서 올리고뉴클레오티드는 안티센스 올리고뉴클레오티드(ASO), 저분자 간섭 RNA(siRNA), 앱타머를 만드는 데 사용되며, 이들은 모두 유전자 발현과 단백질 기능을 조절할 수 있습니다. 이러한 치료법은 유전성 질환, 암, 희귀질환 치료를 위해 연구되고 있으며, 고도로 표적화되고 개인화된 새로운 유형의 약물을 제공합니다. 또한, 진단학에서 합성 올리고뉴클레오티드는 유전자 돌연변이, 병원체, 바이오마커를 검출하기 위한 분석법 개발에 필수적입니다. 예를 들어, 코로나19 팬데믹은 짧은 맞춤형 DNA 프라이머에 의존하는 PCR 분석과 같은 진단 테스트 개발에서 올리고뉴클레오타이드의 중요한 역할을 부각시켰습니다. 유전자 치료, 면역 치료, 정밀의료의 급속한 확장은 맞춤형 올리고뉴클레오티드 합성 서비스에 대한 강력한 수요를 창출하고 있으며, 이는 헬스케어 발전에서 이 기술의 역할을 더욱 확고히 하고 있습니다.
올리고뉴클레오티드 합성 시장의 성장을 가속하는 주요 요인은?
올리고뉴클레오타이드 합성 시장의 성장은 여러 가지 요인에 의해 주도되고 있으며, 각 요인은 시장 확대에 고유한 기여를 하고 있습니다. 주요 요인 중 하나는 치료 개발에서 합성 올리고뉴클레오타이드, 특히 희귀질환 및 복합질환 치료를 위한 유전자 치료에 대한 수요 증가입니다. CRISPR 및 유전자 편집 기술의 급속한 발전은 가이드 RNA 및 유전자 조작에 필수적인 기타 구성 요소로 사용할 수 있는 고품질 올리고뉴클레오타이드의 필요성을 불러일으키고 있습니다. 환자 개개인의 유전자 프로파일에 맞추어 치료하는 맞춤의료 분야가 확대되고 있는 것도 맞춤형 올리고뉴클레오타이드 합성에 대한 수요를 더욱 촉진하고 있습니다. 또한, 차세대 시퀀서 및 분자진단의 보급으로 진단 분석 및 연구에 사용되는 올리고뉴클레오타이드 시장이 크게 확대되고 있습니다. 자동화 및 하이스루풋 합성 등 제조 기술의 발전으로 기업들은 보다 효율적이고 저렴한 비용으로 올리고뉴클레오티드를 생산할 수 있게 되었고, 보다 많은 연구자와 제약회사들이 올리고뉴클레오티드를 이용할 수 있게 되었습니다. 생명공학에 대한 지속적인 투자와 유전체학에 대한 관심이 증가함에 따라 이 시장은 당분간 견조한 성장세를 유지할 것으로 예측됩니다.
부문
제품(올리고뉴클레오티드 기반 의약품, 합성 올리고뉴클레오티드, 시약, 기기), 용도(치료제, 진단 의약품, 연구), 최종 용도(병원, 진단 실험실, 제약 기업 및 바이오테크놀러지 기업, 기타 최종 용도)
조사 대상 기업 예
ATDBio Ltd.
Bio-Synthesis Inc.
Eurogentec
GE Healthcare Life Sciences
GeneDesign, Inc.
GenScript Biotech Corporation
Integrated DNA Technologies(IDT), Inc.
LGC Biosearch Technologies
Merck KgaA
Nitto Denko Avecia Inc.
Thermo Fisher Scientific, Inc.
AI 통합
Global Industry Analysts는 유효한 전문가 컨텐츠와 AI툴에 의해서, 시장 정보와 경쟁 정보를 변혁하고 있습니다.
Global Industry Analysts는 일반적인 LLM나 업계별 SLM 쿼리에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 대량 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.
관세 영향 계수
Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.
목차
제1장 조사 방법
제2장 주요 요약
시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
스페인
러시아
기타 유럽
아시아태평양
호주
인도
한국
기타 아시아태평양
라틴아메리카
아르헨티나
브라질
멕시코
기타 라틴아메리카
중동
이란
이스라엘
사우디아라비아
아랍에미리트(UAE)
기타 중동
아프리카
제4장 경쟁
LSH
영문 목차
영문목차
Global Oligonucleotide Synthesis Market to Reach US$19.9 Billion by 2030
The global market for Oligonucleotide Synthesis estimated at US$8.3 Billion in the year 2024, is expected to reach US$19.9 Billion by 2030, growing at a CAGR of 15.6% over the analysis period 2024-2030. Oligonucleotide-Based Drugs, one of the segments analyzed in the report, is expected to record a 17.3% CAGR and reach US$8.6 Billion by the end of the analysis period. Growth in the Synthesized Oligonucleotides segment is estimated at 15.0% CAGR over the analysis period.
The U.S. Market is Estimated at US$2.2 Billion While China is Forecast to Grow at 21.2% CAGR
The Oligonucleotide Synthesis market in the U.S. is estimated at US$2.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.9 Billion by the year 2030 trailing a CAGR of 21.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.1% and 13.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.2% CAGR.
Global Oligonucleotide Synthesis Market - Key Trends & Drivers Summarized
What Is Oligonucleotide Synthesis and Why Is It Gaining Global Attention?
Oligonucleotide synthesis refers to the chemical process used to create short sequences of nucleotides, the building blocks of DNA and RNA. These synthetic oligonucleotides are essential for a variety of applications, ranging from diagnostics and therapeutics to genetic research and biotechnology. The ability to custom-build DNA or RNA strands through synthetic processes has revolutionized molecular biology, allowing researchers to design specific sequences for targeted genetic interventions, gene editing, and pharmaceutical development. Oligonucleotides play a crucial role in modern biotechnology, supporting applications such as PCR (polymerase chain reaction), DNA sequencing, gene synthesis, and antisense therapeutics. As a key enabling technology, oligonucleotide synthesis underpins breakthroughs in genomics, personalized medicine, and drug discovery, making it indispensable to life sciences and healthcare.
How Is Technology Shaping the Evolution of Oligonucleotide Synthesis?
Technological advancements have been pivotal in the evolution of oligonucleotide synthesis, driving higher precision, scalability, and efficiency in the production process. Innovations such as automated synthesizers and improved solid-phase synthesis methods have significantly accelerated the rate at which oligonucleotides can be manufactured, making it easier to meet the growing demands of pharmaceutical and biotechnology industries. Additionally, recent developments in high-throughput synthesis technology allow for the parallel production of large libraries of oligonucleotides, enabling faster research in fields like gene editing and CRISPR technology. The advent of next-generation sequencing (NGS) technologies has further heightened the need for high-quality oligonucleotides, as precise and custom-designed sequences are critical for NGS workflows. Companies are investing heavily in enhancing the purity, length, and sequence fidelity of synthesized oligonucleotides, pushing the boundaries of what can be achieved in genetic research and molecular diagnostics.
Why Are Oligonucleotides Essential in Therapeutics and Diagnostics?
The rising interest in oligonucleotides for therapeutic and diagnostic applications has been a significant driver for the market. In therapeutics, oligonucleotides are used to create antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and aptamers, all of which can modulate gene expression or protein function. These therapies are being explored for the treatment of genetic disorders, cancers, and rare diseases, offering a new class of drugs that are highly targeted and personalized. Additionally, in diagnostics, synthetic oligonucleotides are critical in the development of assays for detecting genetic mutations, pathogens, and biomarkers. The COVID-19 pandemic, for example, highlighted the critical role of oligonucleotides in the development of diagnostic tests such as PCR assays, which rely on short, custom-designed DNA primers. The rapid expansion of gene therapy, immunotherapy, and precision medicine has created a robust demand for custom oligonucleotide synthesis services, further cementing the role of this technology in advancing healthcare.
What Are the Major Drivers Fueling the Growth of the Oligonucleotide Synthesis Market?
The growth in the oligonucleotide synthesis market is driven by several factors, each contributing uniquely to its expansion. One of the primary drivers is the increasing demand for synthetic oligonucleotides in therapeutic development, particularly for genetic therapies aimed at treating rare and complex diseases. The rapid rise of CRISPR and gene-editing technologies has also fueled the need for high-quality oligonucleotides that can be used as guide RNAs and other components essential for gene manipulation. The growing field of personalized medicine, where treatments are tailored to the genetic profile of individual patients, is further driving the demand for custom oligonucleotide synthesis. Additionally, the widespread adoption of next-generation sequencing and molecular diagnostics has significantly expanded the market for oligonucleotides used in diagnostic assays and research. With advancements in manufacturing technologies, including automation and high-throughput synthesis, companies can now produce oligonucleotides more efficiently and at lower costs, making them accessible to a broader range of researchers and pharmaceutical companies. The continued investment in biotechnology, coupled with an increasing focus on genomics, is expected to sustain robust growth in this market for the foreseeable future.
SCOPE OF STUDY:
The report analyzes the Oligonucleotide Synthesis market in terms of units by the following Segments, and Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 41 Featured) -
ATDBio Ltd.
Bio-Synthesis Inc.
Eurogentec
GE Healthcare Life Sciences
GeneDesign, Inc.
GenScript Biotech Corporation
Integrated DNA Technologies (IDT), Inc.
LGC Biosearch Technologies
Merck KgaA
Nitto Denko Avecia Inc.
Thermo Fisher Scientific, Inc.
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
How Trump's Tariffs Impact the Market? The Big Question on Everyone's Mind
Global Economic Update
Oligonucleotide Synthesis - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Demand for Custom Oligonucleotides in Research and Diagnostics Propels Growth of the Oligonucleotide Synthesis Market Globally
Increased Focus on Gene Editing Technologies, Including CRISPR, Drives the Adoption of Advanced Oligonucleotide Synthesis Techniques
Growing Investment in Genomics and Proteomics Research Expands the Addressable Market Opportunity for Oligonucleotide Synthesis Services
Surging Use of Oligonucleotides as Therapeutic Agents in Oncology and Rare Diseases Spurs Growth in Oligonucleotide Synthesis
Technological Advancements in Automated and High-Throughput Oligonucleotide Synthesizers Propel Efficiency and Accelerate Market Growth
Rising Interest in Personalized Medicine and Precision Therapies Strengthens the Business Case for Oligonucleotide Synthesis in Clinical Applications
Increased Adoption of Oligonucleotides in Molecular Diagnostics and Pathogen Detection Generates Demand for Efficient Synthesis Platforms
Growing Demand for Antisense Oligonucleotides and siRNA Therapeutics Creates New Opportunities for Oligonucleotide Synthesis Providers
Expansion of Gene Therapy and Vaccine Development Using Synthetic Oligonucleotides Drives Long-Term Growth in the Market
Increasing Use of Oligonucleotides in Agricultural Biotechnology Expands Market Opportunities Beyond
Enhanced Stability and Delivery Technologies for Oligonucleotides Propel Growth in Therapeutic Applications
Stringent Regulatory Requirements for Oligonucleotide Synthesis in Therapeutics and Diagnostics Create Challenges and Drive Innovation in Quality Control
The Growing Shift Toward Synthetic Biology and DNA Data Storage Systems Generates Demand for High-Fidelity Oligonucleotide Synthesis
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Oligonucleotide Synthesis Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 3: World Historic Review for Oligonucleotide Synthesis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 4: World 15-Year Perspective for Oligonucleotide Synthesis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Oligonucleotide-Based Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 6: World Historic Review for Oligonucleotide-Based Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 7: World 15-Year Perspective for Oligonucleotide-Based Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Synthesized Oligonucleotides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 9: World Historic Review for Synthesized Oligonucleotides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 10: World 15-Year Perspective for Synthesized Oligonucleotides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 12: World Historic Review for Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 13: World 15-Year Perspective for Reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Equipment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 15: World Historic Review for Equipment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 16: World 15-Year Perspective for Equipment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 18: World Historic Review for Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 19: World 15-Year Perspective for Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 21: World Historic Review for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 22: World 15-Year Perspective for Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 24: World Historic Review for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 25: World 15-Year Perspective for Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 27: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 28: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 29: World Recent Past, Current & Future Analysis for Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 30: World Historic Review for Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 31: World 15-Year Perspective for Diagnostic Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 32: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 33: World Historic Review for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 34: World 15-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 35: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 36: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 37: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Oligonucleotide Synthesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 38: USA Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 39: USA Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 40: USA 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
TABLE 41: USA Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 42: USA Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 43: USA 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
TABLE 44: USA Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 45: USA Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 46: USA 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
CANADA
TABLE 47: Canada Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 48: Canada Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 49: Canada 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
TABLE 50: Canada Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 51: Canada Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 52: Canada 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
TABLE 53: Canada Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 54: Canada Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 55: Canada 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
JAPAN
Oligonucleotide Synthesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 56: Japan Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 57: Japan Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 58: Japan 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
TABLE 59: Japan Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 60: Japan Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 61: Japan 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
TABLE 62: Japan Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 63: Japan Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 64: Japan 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
CHINA
Oligonucleotide Synthesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 65: China Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 66: China Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 67: China 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
TABLE 68: China Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 69: China Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 70: China 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
TABLE 71: China Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 72: China Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 73: China 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
EUROPE
Oligonucleotide Synthesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 74: Europe Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 75: Europe Historic Review for Oligonucleotide Synthesis by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 76: Europe 15-Year Perspective for Oligonucleotide Synthesis by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
TABLE 77: Europe Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 78: Europe Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 79: Europe 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
TABLE 80: Europe Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 81: Europe Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 82: Europe 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
TABLE 83: Europe Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 84: Europe Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 85: Europe 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
FRANCE
Oligonucleotide Synthesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 86: France Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 87: France Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 88: France 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
TABLE 89: France Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 90: France Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 91: France 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
TABLE 92: France Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 93: France Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 94: France 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
GERMANY
Oligonucleotide Synthesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 95: Germany Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 96: Germany Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 97: Germany 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
TABLE 98: Germany Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 99: Germany Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 100: Germany 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
TABLE 101: Germany Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 102: Germany Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 103: Germany 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
ITALY
TABLE 104: Italy Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 105: Italy Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 106: Italy 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
TABLE 107: Italy Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 108: Italy Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 109: Italy 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
TABLE 110: Italy Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 111: Italy Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 112: Italy 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
UNITED KINGDOM
Oligonucleotide Synthesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 113: UK Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 114: UK Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 115: UK 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
TABLE 116: UK Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 117: UK Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 118: UK 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
TABLE 119: UK Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 120: UK Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 121: UK 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
SPAIN
TABLE 122: Spain Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 123: Spain Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 124: Spain 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
TABLE 125: Spain Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 126: Spain Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 127: Spain 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
TABLE 128: Spain Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 129: Spain Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 130: Spain 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
RUSSIA
TABLE 131: Russia Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 132: Russia Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 133: Russia 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
TABLE 134: Russia Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 135: Russia Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 136: Russia 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
TABLE 137: Russia Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 138: Russia Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 139: Russia 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
REST OF EUROPE
TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 141: Rest of Europe Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 142: Rest of Europe 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 144: Rest of Europe Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 145: Rest of Europe 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 147: Rest of Europe Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 148: Rest of Europe 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
ASIA-PACIFIC
Oligonucleotide Synthesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 150: Asia-Pacific Historic Review for Oligonucleotide Synthesis by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 151: Asia-Pacific 15-Year Perspective for Oligonucleotide Synthesis by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 153: Asia-Pacific Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 154: Asia-Pacific 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 156: Asia-Pacific Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 157: Asia-Pacific 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 159: Asia-Pacific Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 160: Asia-Pacific 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
AUSTRALIA
Oligonucleotide Synthesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
TABLE 161: Australia Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 162: Australia Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 163: Australia 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
TABLE 164: Australia Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 165: Australia Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 166: Australia 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
TABLE 167: Australia Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 168: Australia Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 169: Australia 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
INDIA
Oligonucleotide Synthesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
TABLE 170: India Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 171: India Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 172: India 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
TABLE 173: India Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 174: India Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 175: India 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
TABLE 176: India Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 177: India Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 178: India 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
SOUTH KOREA
TABLE 179: South Korea Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 180: South Korea Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 181: South Korea 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
TABLE 182: South Korea Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 183: South Korea Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 184: South Korea 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
TABLE 185: South Korea Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 186: South Korea Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 187: South Korea 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
REST OF ASIA-PACIFIC
TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 189: Rest of Asia-Pacific Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 192: Rest of Asia-Pacific Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 195: Rest of Asia-Pacific Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
LATIN AMERICA
Oligonucleotide Synthesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
TABLE 197: Latin America Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 198: Latin America Historic Review for Oligonucleotide Synthesis by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 199: Latin America 15-Year Perspective for Oligonucleotide Synthesis by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
TABLE 200: Latin America Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 201: Latin America Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 202: Latin America 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
TABLE 203: Latin America Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 204: Latin America Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 205: Latin America 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
TABLE 206: Latin America Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 207: Latin America Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 208: Latin America 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
ARGENTINA
TABLE 209: Argentina Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 210: Argentina Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 211: Argentina 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
TABLE 212: Argentina Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 213: Argentina Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 214: Argentina 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
TABLE 215: Argentina Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 216: Argentina Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 217: Argentina 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
BRAZIL
TABLE 218: Brazil Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 219: Brazil Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 220: Brazil 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
TABLE 221: Brazil Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 222: Brazil Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 223: Brazil 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
TABLE 224: Brazil Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 225: Brazil Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 226: Brazil 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
MEXICO
TABLE 227: Mexico Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 228: Mexico Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 229: Mexico 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
TABLE 230: Mexico Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 231: Mexico Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 232: Mexico 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
TABLE 233: Mexico Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 234: Mexico Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 235: Mexico 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
REST OF LATIN AMERICA
TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 237: Rest of Latin America Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 238: Rest of Latin America 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 240: Rest of Latin America Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 241: Rest of Latin America 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 243: Rest of Latin America Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 244: Rest of Latin America 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
MIDDLE EAST
Oligonucleotide Synthesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
TABLE 245: Middle East Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 246: Middle East Historic Review for Oligonucleotide Synthesis by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 247: Middle East 15-Year Perspective for Oligonucleotide Synthesis by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
TABLE 248: Middle East Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 249: Middle East Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 250: Middle East 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
TABLE 251: Middle East Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 252: Middle East Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 253: Middle East 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
TABLE 254: Middle East Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 255: Middle East Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 256: Middle East 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
IRAN
TABLE 257: Iran Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 258: Iran Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 259: Iran 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
TABLE 260: Iran Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 261: Iran Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 262: Iran 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
TABLE 263: Iran Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 264: Iran Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 265: Iran 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
ISRAEL
TABLE 266: Israel Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 267: Israel Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 268: Israel 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
TABLE 269: Israel Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 270: Israel Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 271: Israel 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
TABLE 272: Israel Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 273: Israel Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 274: Israel 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
SAUDI ARABIA
TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 276: Saudi Arabia Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 277: Saudi Arabia 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 279: Saudi Arabia Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 280: Saudi Arabia 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 282: Saudi Arabia Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 283: Saudi Arabia 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
UNITED ARAB EMIRATES
TABLE 284: UAE Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 285: UAE Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 286: UAE 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
TABLE 287: UAE Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 288: UAE Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 289: UAE 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
TABLE 290: UAE Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 291: UAE Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 292: UAE 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
REST OF MIDDLE EAST
TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 294: Rest of Middle East Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 295: Rest of Middle East 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 297: Rest of Middle East Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 298: Rest of Middle East 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 300: Rest of Middle East Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 301: Rest of Middle East 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
AFRICA
Oligonucleotide Synthesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
TABLE 302: Africa Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 303: Africa Historic Review for Oligonucleotide Synthesis by Product - Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 304: Africa 15-Year Perspective for Oligonucleotide Synthesis by Product - Percentage Breakdown of Value Sales for Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents and Equipment for the Years 2015, 2025 & 2030
TABLE 305: Africa Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 306: Africa Historic Review for Oligonucleotide Synthesis by Application - Therapeutics, Diagnostics and Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 307: Africa 15-Year Perspective for Oligonucleotide Synthesis by Application - Percentage Breakdown of Value Sales for Therapeutics, Diagnostics and Research for the Years 2015, 2025 & 2030
TABLE 308: Africa Recent Past, Current & Future Analysis for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 309: Africa Historic Review for Oligonucleotide Synthesis by End-Use - Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 310: Africa 15-Year Perspective for Oligonucleotide Synthesis by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Laboratories, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030